Nutriband CEO Publishes Letter Outlining 2026 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Nutriband announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The letter read, in part, "As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with us from the beginning and now the many more who have joined our common goal along the way. This goal is to change the world for the better by creating technology designed to improve the safety standard of easily abused transdermal drugs while simultaneously focusing on making these safer treatments available to patients who require them...This coming year we look forward to continuing to stride towards commercialization with AVERSA Fentanyl...Your continued support and belief in our vision have been pivotal to our reaching these milestones and others as we forge ahead. We remain committed to our shareholder value as our number one focus and as we near closer to commercialization for AVERSA product 1, I have no doubt that strategy will shine through."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRB
Wall Street analysts forecast NTRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRB is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.520
Low
15.00
Averages
15.00
High
15.00
Current: 4.520
Low
15.00
Averages
15.00
High
15.00
No data
About NTRB
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nutriband Annual Meeting Update: New Directors and Product Developments
- New Director Appointments: At the Annual Shareholders Meeting on January 24, 2026, Nutriband appointed two new directors, Alessandro Puddu and Viorica Carlig, with Puddu bringing over 10 years of experience in audit and financial reporting, while Carlig adds extensive leadership and compliance expertise, enhancing the company's governance and strategic execution capabilities.
- AVERSA™ FENTANYL Progress: Strengthened collaboration with Kindeva for the exclusive product development of AVERSA™ FENTANYL, where both parties share development costs in exchange for milestone payments, which is expected to accelerate product commercialization and enhance market competitiveness.
- Patent Protection Expansion: Nutriband secured a patent for its AVERSA™ abuse deterrent platform technology in Macao, further solidifying its intellectual property and providing legal protection for global market expansion.
- Shareholder Complaint and Penalties: The company filed a complaint with FINRA to investigate suspected naked short selling and has collected $30,000 in penalties to extend the closing date, which will help protect shareholder interests and bolster market confidence.
Continue Reading
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Shareholder Value Enhancement: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M will add $5M to its bottom line without diluting existing shareholders, demonstrating the company's commitment to shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, thereby enhancing shareholder returns and loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying the groundwork for future commercialization, showcasing its technological edge in drug safety.
- Market Expansion: Nutriband's inclusion in four major indexes, including Russell Microcap and Russell 3000E, enhances its market visibility and investment appeal, potentially attracting more investors to its future growth prospects.
Continue Reading